HER2-NEGATIVE BREAST CANCER
Clinical trials for HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat breast cancer? first human trial underway
Disease control CompletedThis study tested a new drug called OP-1250 in 153 adults with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. The goal was to find the safest dose and see if the drug can shrink tumors. Participants had already tried at least one hormone therapy be…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New test may predict who benefits from targeted breast cancer drug
Knowledge-focused CompletedThis study tested a new lab test (RAD51-foci) to see if it can predict whether the drug olaparib will shrink tumors in people with advanced HER2-negative breast cancer who have certain gene mutations (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D). The study involved 65 participants and…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Knowledge-focused
Last updated May 17, 2026 05:48 UTC
-
Personalized Pre-Surgery breast cancer treatment shows promise in small trial
Knowledge-focused CompletedThis study tested whether adding a drug that targets specific genetic changes found in some breast tumors could slow tumor growth more than standard hormone therapy alone. The trial included 19 people with ER-positive, HER2-negative breast cancer who received treatment before sur…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Jennifer Lee Caswell-Jin • Aim: Knowledge-focused
Last updated May 08, 2026 12:00 UTC